Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Hsiri Therapeutics General Information
Hsiri Therapeutics is developing novel small molecule antibiotics targeting drug-resistant bacterial and fungal pathogens, with a focus on unmet needs such as TB, NTM diseases, and MDR gram-negative bacteria. The company has established partnerships for R&D but no late-stage clinical results are publicly available.
Contact Information
Primary Industry
Biotech
Corporate Office
Media, Pennsylvania
United States
United States
Drug Pipeline
Pre-clinical
Key Partnerships
Shionogi & Co., Ltd. – license agreement and collaborative R&D for TB/NTM therapeutics, U.S. Department of Defense – support for drug discovery efforts, National Institutes of Health – support for drug discovery efforts
Hsiri Therapeutics Funding
No funding data available
To view Hsiri Therapeutics's complete valuation and funding history, request access »